Biotest AG announced that it has appointed Dr. Jörg Schüttrumpf as a further member of the company's management board with effect from January 1, 2022. As Chief Scientific Officer, Dr. Schüttrumpf will be responsible within the Biotest Group for the area of research and development, including drug safety and drug approval. Dr. Schüttrumpf has been responsible for global research at the company since 2012 and for research and development since 2015.